Cliff Asness's CORT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 887,861 shares of Corcept Therapeutics Incorporated (CORT) worth $30.9 M, representing 0.02% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in CORT, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 1.27 M shares. Largest reduction occurred in Q4 2025, reducing 619,348 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Corcept Therapeutics Incorporated (CORT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corcept Therapeutics Incorporated (CORT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -619,348 | Reduce 41.09% | 887,861 | $34.80 |
| Q3 2025 | +1.27 M | Add 546.89% | 1.51 M | $83.11 |
| Q2 2025 | -20,036 | Reduce 7.92% | 232,994 | $73.40 |
| Q1 2025 | -23,561 | Reduce 8.52% | 253,030 | $114.22 |
| Q4 2024 | -39,364 | Reduce 12.46% | 276,591 | $50.39 |
| Q3 2024 | +76,900 | Add 32.17% | 315,955 | $46.28 |
| Q2 2024 | -19,353 | Reduce 7.49% | 239,055 | $32.49 |
| Q1 2024 | +166,975 | Add 182.62% | 258,408 | $25.19 |
| Q4 2023 | +11,488 | Add 14.37% | 91,433 | $32.48 |
| Q3 2023 | +416 | Add 0.52% | 79,945 | $27.25 |
| Q2 2023 | -4,745 | Reduce 5.63% | 79,529 | $22.25 |
| Q1 2023 | +13,487 | Add 19.05% | 84,274 | $21.66 |
| Q4 2022 | -2,172 | Reduce 2.98% | 70,787 | $20.31 |
| Q3 2022 | -18,213 | Reduce 19.98% | 72,959 | $25.64 |
| Q2 2022 | +7,788 | Add 9.34% | 91,172 | $23.78 |
| Q1 2022 | +8,266 | Add 11.00% | 83,384 | $22.52 |
| Q4 2021 | -19,005 | Reduce 20.19% | 75,118 | $19.80 |
| Q3 2021 | -2,875 | Reduce 2.96% | 94,123 | $19.68 |
| Q2 2021 | -6,120 | Reduce 5.93% | 96,998 | $22.00 |
| Q1 2021 | -41,543 | Reduce 28.72% | 103,118 | $23.79 |
| Q4 2020 | -123,166 | Reduce 45.99% | 144,661 | $26.16 |
| Q3 2020 | -52,435 | Reduce 16.37% | 267,827 | $17.41 |
| Q2 2020 | +17,628 | Add 5.82% | 320,262 | $16.82 |
| Q1 2020 | +178,597 | Add 143.99% | 302,634 | $11.89 |
| Q4 2019 | -77,681 | Reduce 38.51% | 124,037 | $12.10 |
| Q3 2019 | +656 | Add 0.33% | 201,718 | $14.13 |
| Q2 2019 | +46,874 | Add 30.40% | 201,062 | $11.15 |
| Q1 2019 | +31,538 | Add 25.71% | 154,188 | $11.74 |
| Q4 2018 | -115,960 | Reduce 48.60% | 122,650 | $13.36 |
| Q3 2018 | -121,115 | Reduce 33.67% | 238,610 | $14.02 |
| Q2 2018 | +11,977 | Add 3.44% | 359,725 | $15.72 |
| Q1 2018 | -363,267 | Reduce 51.09% | 347,748 | $16.45 |
| Q4 2017 | -223,369 | Reduce 23.91% | 711,015 | $18.06 |
| Q3 2017 | +284,811 | Add 43.85% | 934,384 | $19.30 |
| Q2 2017 | +289,958 | Add 80.63% | 649,573 | $11.80 |
| Q1 2017 | +217,323 | Add 152.73% | 359,615 | $10.96 |
| Q4 2016 | +22,313 | Add 18.60% | 142,292 | $7.26 |
| Q3 2016 | +23,175 | Add 23.94% | 119,979 | $6.50 |
| Q2 2016 | -103,929 | Reduce 51.77% | 96,804 | $5.46 |
| Q1 2016 | -90,049 | Reduce 30.97% | 200,733 | $4.68 |
| Q4 2015 | +124,840 | Add 75.23% | 290,782 | $4.98 |
| Q3 2015 | +110,461 | Add 199.10% | 165,942 | $3.76 |
| Q2 2015 | +13,281 | Add 31.47% | 55,481 | $6.00 |
| Q1 2015 | -20,200 | Reduce 32.37% | 42,200 | $5.59 |
| Q4 2014 | -22,800 | Reduce 26.76% | 62,400 | $3.00 |
| Q2 2014 | +26,300 | Add 44.65% | 85,200 | $2.81 |
| Q1 2014 | +58,900 | New Buy | 58,900 | $4.36 |
Cliff Asness's Corcept Therapeutics Incorporated Investment FAQs
Cliff Asness first purchased Corcept Therapeutics Incorporated (CORT) in Q1 2014, acquiring 58,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Corcept Therapeutics Incorporated (CORT) for 48 quarters since Q1 2014.
Cliff Asness's largest addition to Corcept Therapeutics Incorporated (CORT) was in Q3 2025, adding 1,507,209 shares worth $125.26 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 887,861 shares of Corcept Therapeutics Incorporated (CORT), valued at approximately $30.9 M.
As of the Q4 2025 filing, Corcept Therapeutics Incorporated (CORT) represents approximately 0.02% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Corcept Therapeutics Incorporated (CORT) was 1,507,209 shares, as reported at the end of Q3 2025.